The sample loss cost of a cryogenic store is the expected annual damage from a failure: the value of the stored samples, multiplied by the probability of a failure, multiplied by the share of the holding a single event would destroy. That figure tells you how much investment in redundancy, backup storage and monitoring is economically justified.
Most labs, biobanks and cell therapy manufacturers budget for a cryogenic tank as a piece of equipment. The discussion covers purchase price, liquid nitrogen consumption and service contracts. What the tank protects rarely appears in the spreadsheet, even though the contents are almost always worth many times more than the hardware. This article sets out a practical framework: how to value a holding, how to estimate probability and exposure, and how engineering and service measures change the result.
Cryogenic storage failures are rare. When they happen, the damage is rarely contained: a tank that warms up unnoticed puts its entire contents at risk at once. That combination of low probability and very high impact is exactly what makes the risk easy to underestimate, and exactly why it deserves a sober calculation.
Two publicly reported cases from the United States show that the scenario is real. In March 2018, storage tanks failed within days of each other at two fertility clinics, in San Francisco and in Cleveland. According to press reports, several thousand eggs and embryos were affected at each site. In Cleveland, the clinic stated that the tank's remote alarm had been switched off. In the San Francisco litigation, a jury awarded five affected patients around 15 million US dollars in 2021. Beyond the biological material, liability, legal costs and reputation were at stake.
The value of a cryopreserved holding is more than the sum of its vials. A defensible valuation separates four layers.
The first layer is the direct cost of recreating the material: re-establishing cultures, expanding and characterising cell lines again, consumables, staff time and quality control. For research cell lines, project budgets usually give a reasonable figure. For a GMP master or working cell bank, add cleanroom manufacturing, release testing and the full documentation package.
The second layer is often the largest and the hardest to price: many samples simply cannot be collected again. Think of patient material from closed clinical trials, longitudinal cohort samples, rare-disease specimens, autologous cell products and gametes. For these, the question is not what replacement costs but which research, therapy or family plan becomes impossible. Flag such samples separately and value them conservatively high.
The third layer covers everything a loss sets in motion: delayed clinical trials, re-recruiting participants, postponed regulatory milestones, patient doses that cannot be supplied, deviation reports and CAPA, extra audits. In drug development, a delay of a few months can cost more than the entire storage facility.
The fourth layer involves third parties: damages claims, legal fees, insurance premiums, and the trust of patients, sponsors and funders. For biobanks and contract storage providers, that trust is the business.
To support an investment decision, one simple formula is enough. It follows the logic of quality risk management under ICH Q9(R1):
Expected annual loss = holding value × annual failure probability × exposure
A lab keeps cell lines in a single tank and estimates replacement and consequential costs at 2 million euros. It assumes a 1 % annual failure probability. With full exposure, the expected loss is 20,000 euros a year, or 200,000 euros over ten years.
If the lab stores a backup of every cell line in a second tank at another site, the exposure to a total loss drops to almost zero: both containers would have to fail at the same time. Continuous monitoring with alarm escalation further reduces the chance that a failure goes unnoticed, and the expected loss falls again. The figures are assumptions, but the structure transfers to any holding.
You can only reduce probability if you know where failures come from. In practice, the same few patterns recur:
The pattern is clear: most causes do not destroy samples immediately. A well-insulated container holds its temperature for days. What matters is whether someone notices the problem and acts within that hold time.
Every protective measure acts on one of the three factors, which makes investments directly comparable.
A backup tank or second site prevents one event from reaching the whole holding. For critical cell lines, this split is standard practice in many GMP operations. Our article on GMP-compliant backup storage for high-value cell lines explains how to set it up and qualify it.
The Consarctic® Monitoring System records temperature, fill level and events for every container and escalates alarms until someone responds. Biolog® software keeps the data per container. Operators with several sites should bring them into one view, as described in our guide to a centralised cryogenic monitoring system.
An eccentric tank opening with a rotatable bottom reduces heat ingress during access and cuts LN₂ consumption by up to 30 % on Consarctic® cryogenic tanks. Less boil-off means more reserve if the supply fails. Automatic filling with FMCS Touch and NRT3010 refill units removes human error from routine operation. And the Consarctic® 24/7 emergency service reaches sites within hours, 365 days a year.
The test is straightforward: if a measure costs less over its lifetime than the reduction in expected loss it delivers, it pays. For valuable holdings this is almost always the case, because irreplaceability dominates any realistic valuation.
Don't assess the measure in isolation. Purchase, nitrogen, maintenance, monitoring and service belong in a single total cost of ownership for cryogenic systems. Only then does it become visible that a cheaper tank without monitoring can be the more expensive option over ten years.
For biobanks, ISO 20387 requires documented processes for storage, traceability and quality assurance. In GMP environments, EU GMP Annex 15 and installation and operational qualification (IQ/OQ) add further requirements. Consarctic® is certified to EN ISO 13485:2016 and ISO 9001:2015 and performs IQ/OQ with its own certified technicians, serving customers in more than 30 countries. A documented risk calculation also helps in an audit: it shows that safeguards were chosen for a reason, not by accident.
Assess four layers separately: replacement cost, irreplaceability, consequential cost such as trial delays, and liability. Flag samples that cannot be re-collected and value them conservatively high. Do the valuation per container so you can see where value is concentrated.
For valuable or irreplaceable holdings, usually yes. A second container, ideally at a different site, sharply reduces the exposure to any single failure. Compare its lifecycle cost with the reduction in expected loss to confirm it for your own case.
Interrupted liquid nitrogen supply, gradual vacuum loss, operator error, transport, and above all alarms that are switched off or reach nobody. Most faults can be fixed within the hold time if they are noticed in time.
Insurance can offset part of the financial damage, but it cannot replace irreplaceable samples. Insurers also increasingly ask about monitoring, alarm escalation and redundancy. A documented risk calculation supports that conversation too.
Want to know what a failure in your cryogenic store would cost? Talk to the experts at Consarctic®, the market-leading provider of cryogenic technology for the life sciences: we assess your storage infrastructure, design redundancy and monitoring, and deliver the system GMP-ready with IQ/OQ.